Britain and America have announced a major trade agreement that will maintain no tariffs on British medicine shipments entering the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the National Health Service (NHS). This move guarantees that import taxes on these vital goods will remain at nothing for a period of the next three years.
This deal is in response to previous threats to dramatically increase tariffs on branded drug products, with potential rates floated up to 100%.
"This agreement with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to transatlantic medicine commerce," a release said.
Economic Importance
Medicines represent one of the UK's most significant export categories to the US, which is easily the biggest destination for large UK drugmakers.
Export figures show that in the 12 months to the end of September, the UK sold drugs worth billions to the US. This value made up 17.4% of all goods exports in that span.
"This guarantee protects work, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Key UK Commitments
The agreement entails several notable commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a target to double overall public funding on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Industry Background
The deal comes amid a long-running tension between the sector and the ministers over spending levels and approval rates.
These tensions were exacerbated by arguments that American customers were paying several times more for the same drugs than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or scrapped, while major funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the past decade.
